You are here: Accueil -  LV Sacs -  Louis Vuitton Monogram -  Monogram Vernis -  Préparé Louis Vuitton Monogram Vernis Rodeo Drive M93598 Pourpre

Préparé Louis Vuitton Monogram Vernis Rodeo Drive M93598 Pourpre

Préparé Louis Vuitton Monogram Vernis Rodeo Drive M93598 Pourpre

: To evaluate the efficacy of Gamma Knife (GK) radiosurgery in terms of neurologic improvement and tumor growth control (TGC) in a large series of patients with cavernous sinus meningioma Chaussure Louis Vuitton Pour Homme (CSM).

: One hundred thirty-eight patients with CSM (28 males, 110 females; mean age: 56.2 years) were treated with GK between February 1993 and February 2001. GK was used as a first-choice treatment in 68/138 patients and as postoperative adjuvant therapy in 70/138. In 32 patients, it was possible to compare the size Louis Vuitton Damier Azur of the planned treatment volume to tumor volume using the conformity index (CI); optimal CI values were taken to be ≤1.5 (range: 0.94–2.24).

: A follow-up (FU) period of at least 12 months was available for Chaussure Louis Vuitton Monogram 111 patients (median: 48.2 months, range: 12.1–84.5 months). Clinical conditions were improved or stable in 107/111 patients (96.5%). Neurologic recovery was observed in 76% of cases treated by GK alone and in 56.5% of adjuvant treatments (p < 0.03). Adequate TGC was documented in 108/111 tumors (97%), with shrinkage/disappearance in 70/111 (63%) and no variation in volume in 38/111 (34%); the overall actuarial progression-free survival rate at 5 years was 96%. Tumor size regression was observed in 79.5% of patients with FU >30 months, compared with 47.5% of patients with FU <30 months (p < 0.001). One hundred percent TGC was shown in treated patients with a CI ≤1.5 (20/32), compared with 92% TGC in cases with a CI >1.5 (p < 0.15, NS). Radiosurgical sequelae were transient in 4/111 cases (3.5%) and permanent in one case (1%).

: For the FU period of our series (median: >4 years), GK radiosurgery seems to be both safe (permanent morbidity 1%) and effective (96% neurologic improvement/stability, 97% overall TGC, 96% actuarial TGC at 5 years) and might be considered as a first-choice treatment for selected patients with CSM.

0 Commentaires


Speak Your Mind